4 Hepatitis and Liver Disease Flashcards
AST/ALT 15-32 U/L
Normal
AST/ALT 28-75 U/L
Cirrhosis
AST/ALT 40-150
Hepatitis B/C (chronic)
AST/ALT 150-500 U/L
EtOH hepatitis
AST/ALT 300-3000 U/L
Hepatitis C, A, and B (acute)
AST/ALT 500-10,000 U/L
“Shock Liver” or Acetaminophen toxicity
Most common types of liver disease in the US
Non alcoholic fatty liver disease (17-33%)
Non alcoholic steatohepatitis (NASH) (5.7-17%)
Chronic Hep C (1.3%)
Alcoholic Liver Disease (0.8-1.3%)
Hemochromatosis (0.5%)
Chronic Hep B (0.4%)
Hepatitis is a general term for …
Inflammation of the liver
Hepatitis is reflected by …
Abnormal liver tests
Hepatocellular pattern (<10 x ULN)
Predominantly elevated ALT/AST (liver transaminases)
+/- elevated ALP (1/3 present with elevated ALP in NASH)
AST:ALT ratio of >2 is suggestive of…
Alcoholic Liver Disease
ALT>AST is suggestive of…
NASH (AST:ALT ratio usually <1)
Acute or chronic viral hepatitis
Liver Diseases and associated liver enzyme elevation:
Hepatocellular Diseases (ALT/AST elevation predominates)
Nonalcoholic fatty liver disease Genetic hemochromatosis Wilson’s Disease Alpha 1 Antitrypsin Deficiency Autoimmune hepatitis Chronic/acute viral hepatitis Alcoholic Liver Disease Drug toxicity
Liver Diseases and associated liver enzyme elevation:
Cholestatic Diseases (ALP/GGT elevation predominates)
PBC PSC Autoimmune Cholangiopathy Sarcoidosis Biliary Atresia Biliary Obstruction Drug Hepatotoxicity Drug Toxicity
Non-Alcoholic Steatohepatitis (NASH) indicates fatty liver with ______ of liver w/ hepatocyte injury
Inflammation
NASH has a worse prognosis than Fatty Liver because
Higher risk in developing fibrosis and cirrhosis
Liver disease is considered non-alcoholic if …
<20g EtOH/day (less than 2-3 drinks/day)
What are the two subtypes of NonAlcoholic Fatty Liver Disease?
Isolated Steatosis (NAFL) - fatty liver without injury or fibrosis of hepatocytes on bx
Non-Alcoholic Steatohepatitis (NASH) - fatty liver + inflammation = hepatocyte injury; bx +/- fibrosis
Which type of non alcoholic fatty liver disease is more likely to progress to fibrosis/cirrhosis?
NASH - 34-42% will progress, sometimes rapidly (<2 years)
Risk factors for nonalcoholic fatty liver disease
Abdominal obesity DM2 HLD (High TG and Low HDL) Metabolic Syndrome*** (strongest predictor) Genetic factors (PNPLA3, TM6SF2) Age
Strongest predictive risk factor for NAFLD
Metabolic Syndrome
How does NAFLD/NASH present?
Generally asymptomatic
Fatty infiltration incidentally seen on imaging
Exclusion of other causes and no significant EtOH Hx
If obtained, a liver bx in a patient with NAFLD/NASH would show…
Steatosis (fat accumulation)
Inflammation +/- fibrosis
Lab findings in NASH
Hepatocellular pattern
• Mild elevation ALT/AST rarely above 300 IU/Ml
Normal albumin, bilirubin, INR
Ferritin elevated = marker for inflammation
HLD
Glucose elevated (or dx of DM)
ALP elevated in 1/3, GGT frequently elevated too
+/- weakly positive autoimmune factors
What is the main goal in managing NASH patients?
STOP PROGRESSION of cirrhosis
Exercise and weight loss are the cornerstones of management
How is body weight reduction associated with histological improvement in NASH?
> 3% improves steatosis in 35-100% pts
7-10% NASH resolution (64-90% of patients)
≥10% Fibrosis regression seen (45% of patients)
In addition to weight loss and exercise, what else do you do to manage NASH?
Minimize EtOH and modify CVD risk factors
Control DM and HLD (statins OK in compensated cirrhosis)
Monitor LFT after implementation
Vaccinate for Hep A and Hep B if not immune
Liver bx
Is it ok to use statins in patients with NASH?
Yes, so long as they aren’t in decompensated state
Ok to use in compensated cirrhosis
Hereditary disorder of iron metabolism —> accumulation of iron in the liver, pancreas, heart, adrenals, testes, pituitary, skin, and kidney
Hereditary Hemochromatosis
Due to genetic mutation that results in increased GI absorption of iron
How is hereditary hemochromatosis typically found?
Family history or incidentally noted increase in AST/ALT
What ethnic group has the highest incidence of hereditary hemochromatosis?
Caucasians of Northern European Origin
Clinical presentation of hereditary hemochromatosis
Initially non-specific symptoms - fatigue, malaise, RUQ discomfort
Late manifestations (4th-5th decade of life) - hepatomegaly, hepatic insufficiency, cirrhosis, DM, impotence, arthralgia, bronze pigmentation of skin, cardiomegaly w/ or w/o CHF
What is bronze diabetes?
Triad of DM, bronze pigmentation of skin, cirrhosis
Associated with hereditary hemochromatosis
Lab findings for hereditary hemochromatosis
Modest elevation of AST, ALT, Alk Phos
Screen with a serum Fe and TIBC and ferritin
If transferrin sat ≥45 and/or ferritin >200ng/mL for men or >150 ng/mL in women, proceed to GI (HFE mutation analysis)
What is the treatment for hereditary hemochromatosis?
Therapeutic phlebotomy
How is hereditary hemochromatosis diagnosed?
Lab findings confirmed with genetic testing +/- liver biopsy
What is the goal of treatment for hereditary hemochromatosis?
To prevent cirrhosis from iron overload
What patient ed should you give in hereditary hemochromatosis?
Avoid Vit C and iron supplements
Avoid uncooked shellfish esp oysters
Avoid EtOH
Regular phlebotomy (managed by hematologist)
Risk of cirrhosis —> cirrhosis screen q6 months (US +/- AFP)
Genetic screening and iron testing advised for all 1st degree relatives
Who should be screened for hereditary hemochromatosis?
Elevated liver tests (AST/ALT) Abnormal iron studies First degree relative dx with HH Evidence of liver disease Suggestive symptoms of HH
Autosomal recessive mutation —> very rare hereditary disorder of copper metabolism
Wilson’s Disease
Results in decreased excretion of copper into bile and accumulation of copper in liver
In Wilson’s disease, once the liver’s capacity for copper is exceeded, what happens?
Copper is released into the bloodstream —> accumulates in brain, cornea, joints, kidney, heart, and pancreas
Clinical presentation of Wilson’s disease
Usually presents between ages 3-55
Predominantly hepatic, neurologic, and/or psychiatric Sx
• Tremor, dysarthria, incoordination/ataxia, Parkinsonism, personality/behavior changes
Kayser-Fleischer ring + neurologic manifestations is PATHOGNOMONIC
Fine pigmented (brownish or gray green) granular deposits in the cornea, detected either by naked eye or ophthalmoscope
Kayser-Fleischer rings
Together with neurologic manifestions, is pathognomonic for Wilson’s Disease
How is Wilson’s Disease diagnosed?
Mildly elevated AST/ALT with normal/low Alk Phos
Initial screen with serum ceruloplasmin (reduced in 85% of WD)
Opthal eval (for K-F rings)
24 hour urinary copper (increased)
Dx usually confirmed with liver biopsy +/- molecular testing
1st degree relative screening recommended
Treatment for Wilson’s Disease
Chelation with D-penicillamine and Trientine
Done by GI with specialized training in hepatology